このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Atomo Diagnostics バランスシートの健全性

財務の健全性基準チェック /46

Atomo Diagnosticsの総株主資本はA$13.7M 、総負債はA$0.0で、負債比率は0%となります。総資産と総負債はそれぞれA$14.9MとA$1.2Mです。

主要情報

負債資本比率

AU$0

負債

インタレスト・カバレッジ・レシオ	n/a
現金	AU$3.69m
エクイティ	AU$10.08m
負債合計	AU$1.29m
総資産	AU$11.38m

財務の健全性に関する最新情報

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Recent updates

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Jul 05

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Oct 10

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Jun 10

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Dec 06

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Nov 01

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Jul 19

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

Feb 26

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Jan 22

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

Dec 18

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

Jul 16

財務状況分析

短期負債: AT1の短期資産 ( A$9.6M ) が短期負債 ( A$1.1M ) を超えています。

長期負債: AT1の短期資産 ( A$9.6M ) が長期負債 ( A$119.7K ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: AT1は負債がありません。

負債の削減: AT1は現在負債はありませんが、その期間のデータがないため、5 年前と比較することはできません。

貸借対照表

キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: AT1は、現在のフリーキャッシュフローに基づくと、キャッシュランウェイが 1 年未満です。

キャッシュランウェイの予測: フリーキャッシュフローが毎年1.5 % の歴史的率で成長し続ける場合、 AT1のキャッシュランウェイは 1 年未満になります。

Atomo Diagnostics バランスシートの健全性

財務の健全性 基準チェック /46

主要情報

財務の健全性に関する最新情報

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

Recent updates

Full year 2024 earnings released: AU$0.011 loss per share (vs AU$0.017 loss in FY 2023)

Atomo Diagnostics Limited to Report Q2, 2025 Results on Jan 31, 2025

New minor risk - Share price stability

Atomo Diagnostics Limited to Report Fiscal Year 2024 Results on Aug 30, 2024

Atomo Diagnostics Limited to Report First Half, 2024 Results on Jan 29, 2024

Atomo Diagnostics Limited Announces the Resignation of Curt LaBelle as Non-Executive Director

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

Atomo Diagnostics Limited Announces the Departure of William Souter as Chief Financial Officer, Effective 13 December 2023

New major risk - Market cap size

Full year 2023 earnings released: AU$0.017 loss per share (vs AU$0.01 loss in FY 2022)

Atomo Diagnostics Limited, Annual General Meeting, Nov 02, 2023

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

New major risk - Share price stability

Atomo Diagnostics Limited to Report Q4, 2023 Results on Jul 31, 2023

First half 2023 earnings released: AU$0.01 loss per share (vs AU$0.004 loss in 1H 2022)

Atomo Diagnostics Limited Appoints Cheri Walker as an Independent Non-Executive Director

We Think Atomo Diagnostics (ASX:AT1) Can Afford To Drive Business Growth

Atomo Diagnostics Limited, Annual General Meeting, Oct 27, 2022

No longer forecast to breakeven

Full year 2022 earnings: EPS and revenues exceed analyst expectations

Is Atomo Diagnostics (ASX:AT1) In A Good Position To Invest In Growth?

Forecast breakeven date pushed back to 2024

Atomo Diagnostics Limited Expands Executive Team

No longer forecast to breakeven

First half 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$0.31

Atomo Diagnostics Limited to Report First Half, 2022 Results on Feb 21, 2022

Atomo Diagnostics Limited Receives Approval for its Covid-19 Antigen Test in NZ

We're Not Worried About Atomo Diagnostics' (ASX:AT1) Cash Burn

Atomo Diagnostics Limited (ASX:AT1) Shares Could Be 50% Below Their Intrinsic Value Estimate

Full year 2021 earnings released

Consensus revenue estimates fall to AU$7.20m

Forecast breakeven pushed back to 2023

We're Interested To See How Atomo Diagnostics (ASX:AT1) Uses Its Cash Hoard To Grow

Consensus revenue estimates fall to AU$9.60m

Market Sentiment Around Loss-Making Atomo Diagnostics Limited (ASX:AT1)

First half 2021 earnings released: AU$0.005 loss per share (vs AU$0.008 loss in 1H 2020)

Revenue and earnings beat expectations

New 90-day low: AU$0.28

Atomo Diagnostics (ASX:AT1) Is In A Strong Position To Grow Its Business

New 90-day low: AU$0.29

Here's What Atomo Diagnostics Limited's (ASX:AT1) Shareholder Ownership Structure Looks Like

New 90-day low: AU$0.30

Atomo Diagnostics Limited Receives TGA Approval for Atomorapid HIV (1&2) Test

Atomo Diagnostics Limited Receives TGA Approval for Covid19 Antigen Test

New 90-day low: AU$0.33

Atomo Diagnostics Limited Expands Its Existing COVID-19 Rapid Test Partnership with Access Bio LLC

Atomo Diagnostics Limited Enters into an Agreement DIVOC Laboratories to Launch its COVID-19 Antibody Test in the Indian Market

Full year earnings released - AU$0.026 loss per share

Atomo Diagnostics Limited to Report Fiscal Year 2020 Final Results on Nov 02, 2020

New 90-day high - AU$0.45

Atomo Diagnostics Limited to Report Fiscal Year 2020 Results on Aug 31, 2020

When Can We Expect A Profit From Atomo Diagnostics Limited (ASX:AT1)?

財務状況分析

デット・ツー・エクイティの歴史と分析

貸借対照表

キャッシュ・ランウェイ分析

健全な企業の発掘

財務の健全性基準チェック /46